Churg-Strauss Syndrome (Late Phase)

Clinical Guide: Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome) – The Late Phase

1. Comprehensive Introduction & Overview

Eosinophilic Granulomatosis with Polyangiitis (EGPA), historically and commonly referred to as Churg-Strauss Syndrome (CSS), is a rare, systemic, necrotizing small-vessel vasculitis. It is characterized by the triad of asthma, peripheral blood eosinophilia, and extravascular granulomatous inflammation.

The "Late Phase" or "Vasculitic Phase" represents the most critical stage of the disease progression. While the prodromal phase may manifest as atopic disease or allergic rhinitis, and the eosinophilic phase involves tissue infiltration, the late vasculitic phase signals systemic involvement of small-to-medium-sized arteries. During this stage, the disease can become life-threatening, causing multi-organ dysfunction, including cardiac, renal, and neurological involvement.

This guide serves as an authoritative clinical reference for clinicians, researchers, and orthopedic specialists encountering the systemic musculoskeletal and multi-organ manifestations of this condition.

2. Deep-Dive: Mechanisms and Pathophysiology

The transition into the late phase of CSS is driven by a complex interplay between T-helper 2 (Th2) cell-mediated immunity and the activation of eosinophils.

The Pathophysiological Cascade

1. Eosinophil Activation: Eosinophils release cytotoxic proteins, such as major basic protein (MBP), eosinophil peroxidase (EPO), and eosinophil cationic protein (ECP), which induce direct endothelial damage.
2. Granuloma Formation: Extravascular granulomas form in various tissues, including the lungs, skin, and nerves.
3. Vasculitic Damage: The transition to the late phase involves the development of necrotizing vasculitis, likely triggered by ANCA (Antineutrophil Cytoplasmic Antibodies) in approximately 40-50% of patients.
4. Cytokine Environment: Elevated levels of IL-5, IL-4, and IL-13 perpetuate the eosinophilic inflammatory cycle, leading to permanent organ damage if left untreated.

3. Clinical Staging and Grading

The Lanham criteria are traditionally used to define the clinical presence of CSS. However, the progression is categorized into three distinct, often overlapping, phases:

The Three Phases of CSS

• Phase 1 (Prodromal): Characterized by "allergic march" symptoms—late-onset asthma, allergic rhinitis, and nasal polyposis.
• Phase 2 (Eosinophilic): Peripheral blood eosinophilia (>10%) and eosinophilic infiltration of end-organs (e.g., Loeffler’s syndrome, eosinophilic gastroenteritis).
• Phase 3 (Vasculitic - The Late Phase): Systemic necrotizing vasculitis affecting small arteries and veins. This stage is marked by weight loss, fever, malaise, and mononeuritis multiplex.

4. Clinical Indications and Standard Presentation

The late phase of CSS presents with multisystem involvement. Clinicians must maintain a high index of suspicion when asthma patients present with systemic constitutional symptoms.

Key Clinical Indicators

• Neurological: Mononeuritis multiplex (foot drop, wrist drop) is the hallmark of the vasculitic phase, occurring in up to 75% of patients.
• Cardiac: Myocarditis, pericarditis, and endomyocardial fibrosis. This is the leading cause of mortality in the late phase.
• Cutaneous: Palpable purpura, subcutaneous nodules, and necrotic skin ulcers.
• Pulmonary: Pulmonary infiltrates (often migratory), hemoptysis, and severe, corticosteroid-dependent asthma.
• Gastrointestinal: Eosinophilic colitis, mesenteric vasculitis, and abdominal pain.

5. Diagnostic Testing Protocols

Diagnosis in the late phase requires a combination of clinical, serological, and histological evidence.

Essential Diagnostic Workup

1. Complete Blood Count (CBC): Essential for quantifying the degree of peripheral eosinophilia.
2. ANCA Testing: Perinuclear (p-ANCA) is more common in EGPA, typically targeting myeloperoxidase (MPO).
3. Imaging:
   • High-Resolution CT (HRCT): To identify ground-glass opacities, centrilobular nodules, and bronchial wall thickening.
   • Echocardiogram/Cardiac MRI: Critical for screening for cardiomyopathy.
4. Biopsy (Gold Standard): Histopathological evidence of extravascular eosinophils, necrotizing vasculitis, and granulomatous inflammation.
5. Electromyography (EMG): Used to confirm the presence of mononeuritis multiplex.

6. Differential Diagnosis

Differentiating EGPA from other eosinophilic disorders is vital for appropriate management.

• Hypereosinophilic Syndrome (HES): Lacks the vasculitic and asthmatic components characteristic of EGPA.
• Granulomatosis with Polyangiitis (GPA): Usually lacks the significant eosinophilia and asthma profile of EGPA.
• Eosinophilic Asthma: Does not involve systemic vasculitis or organ-specific granulomatous inflammation.
• Parasitic Infection: Must be ruled out as a cause of secondary eosinophilia.

7. Risks, Side Effects, and Therapeutic Management

The treatment of the late phase focuses on inducing and maintaining remission using immunosuppressive strategies.

Standard Therapeutic Approach

• Corticosteroids: High-dose prednisone is the cornerstone of treatment for the acute vasculitic phase.
• Cyclophosphamide: Often reserved for patients with severe, life-threatening organ involvement.
• Rituximab: Increasingly used as a steroid-sparing agent for ANCA-positive disease.
• Mepolizumab: An anti-IL-5 monoclonal antibody, highly effective for the eosinophilic component of the disease.

Potential Risks of Therapy

• Infection: Due to prolonged immunosuppression.
• Bone Density Loss: Induced by chronic corticosteroid use (requires orthopedic monitoring).
• Cytotoxicity: Long-term concerns with cyclophosphamide (bladder toxicity, infertility).

8. Long-Term Prognosis

The prognosis for EGPA has improved significantly with the advent of biological therapies. However, relapse rates remain high.

• Factors for Poor Prognosis (Five-Factor Score):
  • Age > 65 years.
  • Cardiac insufficiency.
  • Renal insufficiency (Creatinine > 1.58 mg/dL).
  • Gastrointestinal involvement.
  • Central nervous system involvement.

Patients require lifelong monitoring for relapses, particularly during corticosteroid tapering.

9. Frequently Asked Questions (FAQ)

1. Is Churg-Strauss Syndrome hereditary?

No, CSS is not considered a hereditary or genetic condition. It is an acquired autoimmune vasculitis.

2. What is the most common cause of death in the late phase?

Cardiac involvement, specifically eosinophilic myocarditis and subsequent heart failure, is the primary cause of mortality.

3. Does the asthma in CSS ever go away?

Usually, the asthma remains a chronic condition, although its severity may fluctuate significantly with treatment.

4. What is "Mononeuritis Multiplex"?

It is a form of nerve damage where multiple individual nerves are affected in different parts of the body, leading to sudden weakness or numbness, such as foot drop.

5. Can exercise help with the musculoskeletal symptoms?

Yes, under medical supervision, physical therapy is vital for rehabilitating patients who have suffered nerve damage or steroid-induced muscle weakness.

6. Are there specific triggers for a flare-up?

While not fully understood, viral infections and the rapid tapering of corticosteroids are common triggers for disease flares.

7. How long does treatment last?

Treatment is long-term. Even after achieving remission, patients are often kept on low-dose maintenance therapy to prevent relapse.

8. Is this the same as "Eosinophilic Asthma"?

No. While asthma is a component of EGPA, EGPA is a systemic disease involving vasculitis, whereas simple eosinophilic asthma is localized to the lungs.

9. What is the role of Mepolizumab?

Mepolizumab blocks IL-5, a cytokine essential for eosinophil survival. It is highly effective in reducing eosinophil counts and preventing asthma exacerbations in EGPA patients.

10. Should patients with CSS see an Orthopedist?

If there is evidence of peripheral nerve damage (mononeuritis multiplex) causing gait instability, or if the patient has developed steroid-induced osteoporosis, orthopedic or physiatry consultation is highly recommended.

10. Conclusion

The late phase of Churg-Strauss Syndrome (EGPA) is a sophisticated clinical challenge that requires a multidisciplinary approach. By understanding the transition from the prodromal allergic phase to the systemic vasculitic phase, clinicians can implement aggressive, targeted immunotherapy to preserve organ function and improve patient quality of life. Early detection of mononeuritis and cardiac dysfunction remains the highest priority for the clinical management of this condition.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and does not replace professional medical advice, diagnosis, or treatment. Always consult with a rheumatology specialist regarding the management of vasculitic conditions.